

Ref: FOI/GS/ID 9431

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

25 October 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Melanoma.

You asked: All questions are shown as received by the Trust.

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- a. *Cobimetinib*
- b. *Dabrafenib*
- c. *Dabrafenib + Trametinib*
- d. *Dacarbazine*
- e. *Denosumab*
- f. *Encorafenib + Binimetinib*
- g. *Ipilimumab monotherapy*
- h. *Ipilimumab + Nivolumab*
- i. *Nivolumab monotherapy*
- j. *Nivolumab + Relatlimab*
- k. *Pembrolizumab*
- l. *Trametinib*
- m. *Vemurafenib*
- n. *Vemurafenib + Cobimetinib*
- o. *Other active systemic anti-cancer therapy*
- p. *Palliative care only*

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- a. *Ipilimumab monotherapy*
- b. *Ipilimumab + Nivolumab*
- c. *Nivolumab monotherapy*
- d. *Nivolumab + Relatlimab*
- e. *Pembrolizumab*

f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)

g. Other active systemic anti-cancer therapy

h. Palliative care only

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

a. Ipilimumab (monotherapy)

b. Nivolumab (monotherapy)

c. Nivolumab AND Ipilimumab (combination)

d. Nivolumab AND Relatlimab

e. Pembrolizumab

f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)

g. Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Trust response:

| | |
|----|----|
| Q1 | |
| a. | 0 |
| b. | 0 |
| c. | 21 |
| d. | 3 |
| e. | 1 |
| f. | 25 |
| g. | 0 |
| h. | 6 |
| i. | 13 |
| j. | 4 |
| k. | 59 |
| l. | 0 |
| m. | 1 |
| n. | 0 |
| o. | 6 |
| p. | 0 |
| Q2 | |
| a. | 0 |
| b. | 1 |
| c. | 9 |
| d. | 2 |
| e. | 18 |
| f. | 15 |
| g. | 4 |
| h. | 0 |
| Q3 | |

| | |
|----|----|
| a. | 0 |
| b. | 0 |
| c. | 5 |
| d. | 4 |
| e. | 12 |
| f. | 7 |
| g. | 6 |

FOI RESPONSE COPY